Dimensional Fund Advisors LP Buys 210,260 Shares of Charles River Laboratories International, Inc. $CRL

Dimensional Fund Advisors LP raised its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 14.6% during the first quarter, Holdings Channel reports. The fund owned 1,652,484 shares of the medical research company’s stock after buying an additional 210,260 shares during the period. Dimensional Fund Advisors LP’s holdings in Charles River Laboratories International were worth $285,001,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. KBC Group NV lifted its stake in Charles River Laboratories International by 16.3% in the first quarter. KBC Group NV now owns 1,588 shares of the medical research company’s stock valued at $274,000 after purchasing an additional 222 shares during the last quarter. Assetmark Inc. raised its stake in shares of Charles River Laboratories International by 19.6% in the first quarter. Assetmark Inc. now owns 52,387 shares of the medical research company’s stock valued at $9,037,000 after buying an additional 8,578 shares during the period. Wealthfront Advisers LLC lifted its position in shares of Charles River Laboratories International by 17.8% during the 1st quarter. Wealthfront Advisers LLC now owns 1,609 shares of the medical research company’s stock valued at $278,000 after buying an additional 243 shares during the last quarter. Illinois Municipal Retirement Fund bought a new position in shares of Charles River Laboratories International during the 1st quarter worth $774,000. Finally, Procyon Advisors LLC grew its stake in shares of Charles River Laboratories International by 30.2% during the 1st quarter. Procyon Advisors LLC now owns 1,538 shares of the medical research company’s stock worth $265,000 after acquiring an additional 357 shares during the period. 98.91% of the stock is owned by institutional investors.

Charles River Laboratories International Stock Performance

Charles River Laboratories International stock opened at $218.44 on Thursday. The firm’s 50 day simple moving average is $195.88 and its 200 day simple moving average is $187.04. The company has a current ratio of 1.36, a quick ratio of 1.03 and a debt-to-equity ratio of 0.90. Charles River Laboratories International, Inc. has a 1-year low of $144.26 and a 1-year high of $237.86. The firm has a market capitalization of $10.52 billion, a PE ratio of -58.09, a price-to-earnings-growth ratio of 2.44 and a beta of 1.40.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings results on Thursday, May 7th. The medical research company reported $2.06 EPS for the quarter, beating analysts’ consensus estimates of $1.96 by $0.10. The firm had revenue of $995.83 million during the quarter, compared to analyst estimates of $977.46 million. Charles River Laboratories International had a negative net margin of 4.59% and a positive return on equity of 15.36%. The business’s revenue for the quarter was up 1.2% on a year-over-year basis. During the same period in the previous year, the business earned $2.34 EPS. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. As a group, analysts expect that Charles River Laboratories International, Inc. will post 11.05 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the stock. Sanford C. Bernstein set a $250.00 target price on shares of Charles River Laboratories International in a research note on Wednesday, July 1st. Evercore reiterated an “outperform” rating and issued a $220.00 price objective on shares of Charles River Laboratories International in a research note on Friday, May 8th. BNP Paribas Exane set a $250.00 target price on shares of Charles River Laboratories International in a report on Wednesday, July 1st. Citigroup restated a “buy” rating on shares of Charles River Laboratories International in a research report on Wednesday, July 8th. Finally, Robert W. Baird set a $213.00 price target on Charles River Laboratories International in a research report on Friday, May 8th. Eleven equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $220.75.

Insider Buying and Selling at Charles River Laboratories International

In related news, Director James C. Foster sold 75,000 shares of the firm’s stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $225.00, for a total value of $16,875,000.00. Following the sale, the director directly owned 31,596 shares of the company’s stock, valued at $7,109,100. This trade represents a 70.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 1.30% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.